Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03116828 · ClinicalTrials.gov registry record · Phase 4
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
A Phase 4 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 4
- Development phase
- 102
- Enrollment target
NCT03116828 is a Phase 4 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 102 participants.
The verdict
NCT03116828, a Phase 4 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 102 participants
- Enrollment target
Study Summary
A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures
Interventions
- DRUG Eslicarbazepine acetate
- DRUG Eslicarbazepine Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2017-07-07 |
| Est. Completion | 2019-06-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03116828
The ClinicalTrials.gov registry entry for NCT03116828 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eslicarbazepine acetate is the first listed.
NCT03116828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03116828 about?
NCT03116828 is a clinical study titled "A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures". A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures
What is the current status of trial NCT03116828?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 102 participants. The study started on 2017-07-07. Estimated completion is 2019-06-06.
What interventions are being tested in trial NCT03116828?
The interventions under investigation include: Eslicarbazepine acetate (DRUG), Eslicarbazepine Acetate (DRUG).
Who is sponsoring clinical trial NCT03116828?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.